LGT Financial Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$509K Buy
2,022
+508
+34% +$109K 2.69% 6
2026
Q1
$329K Buy
1,514
+6
+0.4% +$1.33K 1.69% 8
2025
Q4
$345K Buy
1,508
+6
+0.4% +$1.37K 2.11% 8
2025
Q3
$348K Buy
1,502
+7
+0.5% +$1.43K 0.75% 33
2025
Q2
$277K Buy
1,495
+68
+5% +$12.6K 0.7% 32
2025
Q1
$299K Sell
1,427
-349
-20% -$67.8K 0.91% 28
2024
Q4
$316K Buy
1,776
+11
+0.6% +$2.02K 0.7% 27
2024
Q3
$348K Sell
1,765
-663
-27% -$124K 0.86% 27
2024
Q2
$416K Sell
2,428
-336
-12% -$55.7K 0.88% 24
2024
Q1
$503K Buy
2,764
+19
+0.7% +$3.27K 0.58% 32
2023
Q4
$425K Sell
2,745
-241
-8% -$35.1K 0.52% 38
2023
Q3
$445K Sell
2,986
-480
-14% -$70.5K 0.57% 29
2023
Q2
$467K Buy
3,466
+522
+18% +$76.5K 0.5% 53
2023
Q1
$469K Buy
2,944
+21
+0.7% +$3.21K 0.87% 20
2022
Q4
$472K Buy
+2,923
New +$448K 0.56% 35

Other funds holding ABBV

LGT Financial Advisors's ABBV Position: Q2 2026 in Review

LGT Financial Advisors increased its AbbVie (ABBV) stake by 34% in Q2 2026, buying an estimated $109K and bringing the position to 2,022 shares worth $509K. The position accounts for 2.69% of the portfolio, ranked #6.

LGT Financial Advisors first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • LGT Financial Advisors held 2,022 shares of AbbVie worth $509K as of Q2 2026.
  • LGT Financial Advisors bought 508 AbbVie shares in Q2 2026, an estimated $109K.
  • AbbVie made up 2.69% of LGT Financial Advisors's portfolio in Q2 2026, its #6 holding.
  • LGT Financial Advisors first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on LGT Financial Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.